Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis

Ashutosh K. Mangalam, Joseph A Murray

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: The gut microbiome helps to maintain a person’s healthy state while perturbations in its function often leading to the development of inflammatory diseases including multiple sclerosis (MS). Consequently, gut-commensals which restore homeostasis have the potential to become novel therapeutic options for treating MS. MS patients have presented gut dysbiosis with a reduction in bacteria belonging to the Prevotella genus. Notably, increased levels of Prevotella are observed when disease-modifying therapies are used. Additionally, Prevotella histicola, an anaerobic bacterium derived from the human, can suppress disease in mice with experimental autoimmune encephalomyelitis, a preclinical MS model. Areas covered: This review compares MS microbiome studies from different geographical regions to identify common gut bacteria. Literature on the potential use of P. histicola as a therapy for MS and the next steps for developing microbial monotherapies in MS is also discussed. Expert commentary: Recent findings presenting an inverse correlation between Prevotella and MS disease severity and ability of P. histicola to suppress disease in preclinical models suggest that P. histicola might provide an additional treatment option for MS patients. However, rigorous testing in well-designed control trials should be performed to determine the safety and efficacy P. histicola in MS patients.

Original languageEnglish (US)
Pages (from-to)45-53
Number of pages9
JournalExpert Review of Neurotherapeutics
Volume19
Issue number1
DOIs
StatePublished - Jan 2 2019

Fingerprint

Prevotella
Multiple Sclerosis
Dysbiosis
Bacteria
Autoimmune Experimental Encephalomyelitis
Anaerobic Bacteria
Microbiota
Therapeutics
Homeostasis

Keywords

  • bacteria as drug (brug)
  • experimental autoimmune encephalomyelitis (EAE)
  • gut dysbiosis
  • gut microbiota
  • immunomodulation
  • Multiple sclerosis
  • Prevotella
  • Prevotella histicola
  • treatment
  • Tregs

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)

Cite this

Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis. / Mangalam, Ashutosh K.; Murray, Joseph A.

In: Expert Review of Neurotherapeutics, Vol. 19, No. 1, 02.01.2019, p. 45-53.

Research output: Contribution to journalReview article

@article{32e5f9c72f7844a68ee871c50ceac9e4,
title = "Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis",
abstract = "Introduction: The gut microbiome helps to maintain a person’s healthy state while perturbations in its function often leading to the development of inflammatory diseases including multiple sclerosis (MS). Consequently, gut-commensals which restore homeostasis have the potential to become novel therapeutic options for treating MS. MS patients have presented gut dysbiosis with a reduction in bacteria belonging to the Prevotella genus. Notably, increased levels of Prevotella are observed when disease-modifying therapies are used. Additionally, Prevotella histicola, an anaerobic bacterium derived from the human, can suppress disease in mice with experimental autoimmune encephalomyelitis, a preclinical MS model. Areas covered: This review compares MS microbiome studies from different geographical regions to identify common gut bacteria. Literature on the potential use of P. histicola as a therapy for MS and the next steps for developing microbial monotherapies in MS is also discussed. Expert commentary: Recent findings presenting an inverse correlation between Prevotella and MS disease severity and ability of P. histicola to suppress disease in preclinical models suggest that P. histicola might provide an additional treatment option for MS patients. However, rigorous testing in well-designed control trials should be performed to determine the safety and efficacy P. histicola in MS patients.",
keywords = "bacteria as drug (brug), experimental autoimmune encephalomyelitis (EAE), gut dysbiosis, gut microbiota, immunomodulation, Multiple sclerosis, Prevotella, Prevotella histicola, treatment, Tregs",
author = "Mangalam, {Ashutosh K.} and Murray, {Joseph A}",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/14737175.2019.1555473",
language = "English (US)",
volume = "19",
pages = "45--53",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis

AU - Mangalam, Ashutosh K.

AU - Murray, Joseph A

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Introduction: The gut microbiome helps to maintain a person’s healthy state while perturbations in its function often leading to the development of inflammatory diseases including multiple sclerosis (MS). Consequently, gut-commensals which restore homeostasis have the potential to become novel therapeutic options for treating MS. MS patients have presented gut dysbiosis with a reduction in bacteria belonging to the Prevotella genus. Notably, increased levels of Prevotella are observed when disease-modifying therapies are used. Additionally, Prevotella histicola, an anaerobic bacterium derived from the human, can suppress disease in mice with experimental autoimmune encephalomyelitis, a preclinical MS model. Areas covered: This review compares MS microbiome studies from different geographical regions to identify common gut bacteria. Literature on the potential use of P. histicola as a therapy for MS and the next steps for developing microbial monotherapies in MS is also discussed. Expert commentary: Recent findings presenting an inverse correlation between Prevotella and MS disease severity and ability of P. histicola to suppress disease in preclinical models suggest that P. histicola might provide an additional treatment option for MS patients. However, rigorous testing in well-designed control trials should be performed to determine the safety and efficacy P. histicola in MS patients.

AB - Introduction: The gut microbiome helps to maintain a person’s healthy state while perturbations in its function often leading to the development of inflammatory diseases including multiple sclerosis (MS). Consequently, gut-commensals which restore homeostasis have the potential to become novel therapeutic options for treating MS. MS patients have presented gut dysbiosis with a reduction in bacteria belonging to the Prevotella genus. Notably, increased levels of Prevotella are observed when disease-modifying therapies are used. Additionally, Prevotella histicola, an anaerobic bacterium derived from the human, can suppress disease in mice with experimental autoimmune encephalomyelitis, a preclinical MS model. Areas covered: This review compares MS microbiome studies from different geographical regions to identify common gut bacteria. Literature on the potential use of P. histicola as a therapy for MS and the next steps for developing microbial monotherapies in MS is also discussed. Expert commentary: Recent findings presenting an inverse correlation between Prevotella and MS disease severity and ability of P. histicola to suppress disease in preclinical models suggest that P. histicola might provide an additional treatment option for MS patients. However, rigorous testing in well-designed control trials should be performed to determine the safety and efficacy P. histicola in MS patients.

KW - bacteria as drug (brug)

KW - experimental autoimmune encephalomyelitis (EAE)

KW - gut dysbiosis

KW - gut microbiota

KW - immunomodulation

KW - Multiple sclerosis

KW - Prevotella

KW - Prevotella histicola

KW - treatment

KW - Tregs

UR - http://www.scopus.com/inward/record.url?scp=85059290553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059290553&partnerID=8YFLogxK

U2 - 10.1080/14737175.2019.1555473

DO - 10.1080/14737175.2019.1555473

M3 - Review article

C2 - 30513004

AN - SCOPUS:85059290553

VL - 19

SP - 45

EP - 53

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 1

ER -